These data suggest that structural analogs of curcumin which retain the ability to inhibit the STAT3 oncogenic signaling pathways while leaving the STAT1 tumor suppressor pathway, and immune effector function intact could be most useful for cancer therapy. This evidence concerns the gene STAT3 and neoplasm.